insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Company profile
Ticker
PODD
Exchange
Website
CEO
Shacey Petrovic
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Insulet Asia (Singapore) Pte. Ltd. • Insulet Austria GmbH • Insulet Australia Pty Ltd • Insulet Canada Corporation • Insulet Consulting (Shenzhen) Co., Ltd. • Insulet France SAS • Insulet Germany GmbH • Insulet International Holdings Ltd. • Insulet International Ltd. • Insulet MA Securities Corporation ...
IRS number
43523891
PODD stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
8-K
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
20 Mar 24
8-K
Departure of Directors or Certain Officers
1 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth
22 Feb 24
8-K
Entry into a Material Definitive Agreement
25 Jan 24
8-K
Insulet Announces Changes to Board of Directors with Retirements and New Appointments
18 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
S-8
Registration of securities for employees
2 Nov 23
Transcripts
PODD
Earnings call transcript
2023 Q4
22 Feb 24
PODD
Earnings call transcript
2023 Q3
2 Nov 23
PODD
Earnings call transcript
2023 Q2
8 Aug 23
PODD
Earnings call transcript
2023 Q1
4 May 23
PODD
Earnings call transcript
2022 Q4
23 Feb 23
PODD
Earnings call transcript
2022 Q3
4 Nov 22
PODD
Earnings call transcript
2022 Q2
7 Aug 22
PODD
Earnings call transcript
2022 Q1
6 May 22
PODD
Earnings call transcript
2021 Q4
24 Feb 22
PODD
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 685.40 mm | 685.40 mm | 685.40 mm | 685.40 mm | 685.40 mm | 685.40 mm |
Cash burn (monthly) | (no burn) | 4.31 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 28.64 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 656.76 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 152.4 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
98.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 514 |
Opened positions | 85 |
Closed positions | 128 |
Increased positions | 195 |
Reduced positions | 181 |
13F shares | Current |
---|---|
Total value | 10.99 tn |
Total shares | 68.96 mm |
Total puts | 855.00 k |
Total calls | 667.00 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 8.00 mm | $1.28 tn |
Capital Research Global Investors | 7.92 mm | $1.26 tn |
FMR | 6.58 mm | $1.05 tn |
BLK Blackrock | 6.00 mm | $956.41 bn |
Wellington Management | 3.03 mm | $483.98 bn |
STT State Street | 2.83 mm | $451.96 bn |
Capital World Investors | 2.37 mm | $378.57 bn |
D1 Capital Partners | 1.82 mm | $290.42 bn |
Geode Capital Management | 1.57 mm | $249.58 bn |
Clearbridge Advisors | 1.43 mm | $228.21 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 24 | Petrovic Shacey | Common Stock | Sell | Dispose S | No | No | 162.92 | 11,609 | 1.89 mm | 2,567 |
28 Feb 24 | Petrovic Shacey | Common Stock | Option exercise | Acquire M | No | No | 92.11 | 11,609 | 1.07 mm | 14,176 |
28 Feb 24 | Petrovic Shacey | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 92.11 | 11,609 | 1.07 mm | 0 |
28 Feb 24 | Prem Singh | Common Stock | Payment of exercise | Dispose F | No | No | 163.6 | 90 | 14.72 k | 5,400 |
28 Feb 24 | Dan Manea | Common Stock | Payment of exercise | Dispose F | No | No | 163.6 | 168 | 27.48 k | 7,496 |
28 Feb 24 | Kapples John W. | Common Stock | Payment of exercise | Dispose F | No | No | 163.6 | 263 | 43.03 k | 19,130 |
28 Feb 24 | James Hollingshead | Common Stock | Payment of exercise | Dispose F | No | No | 163.6 | 908 | 148.55 k | 45,572 |
27 Feb 24 | Prem Singh | Common Stock | Grant | Acquire A | No | No | 0 | 2,100 | 0.00 | 5,490 |
27 Feb 24 | Prem Singh | Stock Option Common Stock | Grant | Acquire A | No | No | 166.62 | 5,031 | 838.27 k | 5,031 |
27 Feb 24 | Dan Manea | Common Stock | Grant | Acquire A | No | No | 0 | 2,250 | 0.00 | 7,664 |
News
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
29 Feb 24
On Thursday February 22, Insulet Gave Q1 2024 Revenue Growth Guidance Of 17%-20%; For FY24, The Company Expects Revenue Growth In The Range Of 12%-17%
26 Feb 24
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
26 Feb 24
JP Morgan Maintains Overweight on Insulet, Raises Price Target to $225
23 Feb 24
Analyst Scoreboard: 5 Ratings For Insulet
23 Feb 24
Press releases
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
20 Mar 24
Insulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
8 Mar 24
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
5 Mar 24
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
13 Feb 24
Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
7 Feb 24